A new imaging method for detecting tumors early
A new highly sensitive targeted imaging method for early tumor detection
This study is working on a new way to spot tumors early by using special imaging agents that target a specific marker in tumor blood vessels, which could help improve cancer detection and treatment for everyone.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10837132 on NIH RePORTER |
What this research studies
This research focuses on developing a highly sensitive imaging technique that targets a specific marker found in tumor blood vessels, known as the Follicle Stimulating Hormone Receptor (FSHR). The approach involves creating imaging agents that bind to FSHR and testing their effectiveness in cell cultures and in mice with implanted human tumors. By identifying tumors at their earliest stages, this method aims to improve early detection, which is crucial for successful treatment outcomes. The ultimate goal is to contribute to national efforts in reducing cancer mortality through better screening methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of developing cancer, particularly those with a family history or other risk factors.
Not a fit: Patients with advanced-stage cancers that are already symptomatic may not benefit from this early detection method.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection of various cancers, significantly improving treatment outcomes and survival rates.
How similar studies have performed: Previous research has shown promise in using targeted imaging techniques for cancer detection, suggesting that this approach could be a valuable advancement in the field.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Radu, Aurelian — Icahn School of Medicine at Mount Sinai
- Study coordinator: Radu, Aurelian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.